Top Biotech Penny Stocks to Watch

Top Biotech Penny Stocks to Watch

Many biotech companies trade as penny stocks as when they are new to the market. With the acceptability of their products in the market, the stocks shoot up in price and there is upward trend seen for them in the stock market. A worthy biotech company is usually taken by a larger group to make its value go upwards. Penny stock investments require a lot of research and biotech stocks under this category are no different. The successful penny stocks are a resultant of the consistent efforts by the company in bringing the best out of their efforts to establish a positive range of stocks.

Top Biotech Penny Stocks to Watch

  1. Pacific Biosciences of California, Inc. (PACB): Pacific Biosciences of California, Inc. was founded in 2004 and it works to develop and manufacturer the gene sequencing systems along with some real-time biological observation. The stock was traded at $17 in the past but in the last year, the value subsided to $2.2 value. The present stock value is $7.26 and the company has a strong solvency position with a quick ratio of over 3.5 value.
  2. Celldex Therapeutics Inc. (CLDX): This biopharma company has prime focus on developing and commercializing the immunotherapy technology and other cancer-targeting issues. Cancer focusing companies are highly admired by the investors as the cure has lucrative results for a majority of people in the industry. CLDX has a lot of drugs ready for testing phase and once it goes through, there will be many positive prospects for the sector. The stocks are valued at $4.34 at present and the 52-week high price is $34. It means that the company has a huge scope and the stocks can be purchased for long-term projections.
  3. Neuralstem, Inc. (CUR): This is a clinical-stage biopharma company having R&D for nervous system disorders with the basis of working on neuronal stem cells and small molecular compounds. The company’s stocks are priced at 45 cents value at the present and there is a huge target set up by the company for the annual growth. The prospects are good and the company might reach to upward levels in the coming phases.
  4. Egalet Corporation (EGLT): This is a pharma company working for development, manufacturing, and commercialization for the patient treatment having acute pain and other related issues. The patented time-release treatment for subsiding the pain has been the strength in developing the optimistic clinical results. The company has shown sales growth over 90 percent in the past five years. The stocks are priced at 52-weeks low value of $0.086. This could be a buying phase for the investors looking for a long-term growth by trusting the stocks to upward levels.
  5. Curis, Inc. (CRIS): This biotech company works in the development of drugs for cancer treatment in the US. The company has got increased sales and EPS in every quarter with a value of over 30 percent. This stock prices are about $2.28 and the company is working on getting the price target over $5.